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Abstract
Purpose Identifying gastroduodenal uptake of
99mTc-
macroaggregated albumin (MAA), which is associated with
an increased risk of ulcer disease, is a crucial part of the
therapeutic management of patients undergoing radioembo-
lization for liver tumours. Given this context, the use of
MAA single photon emission computed tomography
(SPECT)/CT may be essential, but the procedure has still
not been thoroughly evaluated. The aim of this retrospective
study was to determine the effectiveness of MAA SPECT/CT
in identifying digestive extrahepatic uptake, while determin-
ing potential diagnostic pitfalls.
Methods Overall, 139 MAA SPECT/CTscans were performed
on 103 patients with different hepatic tumour types. Patients
were followed up for at least 6 months according to standard
requirements.
Results Digestive, or digestive-like, uptake other than free
pertechnetate was identified in 5.7% of cases using planar
imaging and in 36.6% of cases using SPECT/CT. Uptake
sites identified by SPECT/CT included the gastroduodenal
region (3.6%), gall bladder (12.2%), portal vein thrombosis
(6.5%), hepatic artery (6.5%), coil embolization site (2.1%)
as well as falciform artery (5.0%). For 2.1% of explorations,
a coregistration error between SPECT and CT imaging
could have led to a false diagnosis by erroneously attribut-
ing an uptake site to the stomach or gall bladder, when the
uptake actually occurred in the liver.
Conclusion SPECT/CT is more efficacious than planar imag-
ing in identifying digestive extrahepatic uptake sites, with extra-
hepatic uptake observed in one third of scans using the former
procedure. However, more than half of the uptake sites in our
study were vascular in nature, without therapeutic implications.
T h er i s ko fc o r e g i s t r a t i o ne r r o r sm u s ta l s ob ek e p ti nm i n d .
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Introduction
Radioembolization based on microspheres labelled with
90Y
has emerged as a valuable therapy that is increasingly being
used for patients with liver tumours [1–3]. In contrast to
131I-lipiodol therapy, this therapeutic approach has not only
shown efficacy in patients with hepatic carcinomas, but the
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5]. In addition to its efficacy and association with fewer
constraints in terms of radiation protection, another distinct
advantage of the technique is its low toxicity profile. In
addition, this therapeutic strategy is associated with a low risk
of pulmonary complications or gastroduodenal ulcer disease
when these structures are irradiated. Therefore, due to safety
concerns, this technique requires an initial diagnostic angiog-
raphy followed by hepatic arterial perfusion scintigraphy
using
99mTc-labelled albumin macroaggregates (MAA) in
order to identify potential pulmonary or digestive shunts.
While the technique has been primarily used to identify
pulmonary shunts, with the development of single photon
emission computed tomography (SPECT)/CT imaging,
MAA scintigraphy is now increasingly being used to detect
digestive shunts, which may constitute a contraindication to
this type of therapy. Recently, a number of studies revealed
the usefulness of SPECT/CT in identifying gastroduodenal
uptake sites, notably in cases where no arterial shunts had
been detected on angiography [6–9]. Nonetheless, MAA
SPECT/CT semiology has not been fully established.
The aim of this retrospective study was to determine the
usefulness of MAA SPECT/CTin identifying digestive extra-
hepatic uptake sites, corresponding to digestive shunts that
were likely to alter the therapeutic planning, while determin-
ing potential diagnostic pitfalls.
Materials and methods
Data from 139 MAA SPECT/CT scintigraphic explorations
involving 103 consecutive patients (79 men and 24 women)
undergoing
90Y-microsphere therapy were analysed retrospec-
tively. The choice of selective internal radiation therapy (SIRT)
was taken by a multidisciplinary team focused on liver cancer
management. Regarding tumour types, 78 patients suffered
from hepatocellular carcinoma (HCC), 13 from cholangiocar-
cinoma and 12 from hepatic metastases (neuroendocrine, n07;
colorectal, n03; choroid melanoma, n02). Written informed
consent was obtained from each patient. Prior to microsphere
therapy, primary diagnostic selective hepatic angiography was
performed in all patients, along with coil embolization of
digestive arteries as appropriate, which was followed by
MAA scintigraphy. In 89 patients,
90Y-microsphere therapy
was conducted (glass microsphere, n084; resin microspheres,
n06), the treatment being contraindicated in 14 patients due to
excessive pulmonary shunting in 5, non-correctable digestive
shunting in 2, insufficient tumour targeting in 6 and hepatic
deterioration occurring between diagnostic angiography and
therapy initiation in the remaining patient.
After selectively injecting 185 MBq MAA into the right or
left hepatic artery, MAA scintigraphy was performed using
planar imaging (256×256, 5 min) and SPECT/CT (32
projections, 128×128, 180° and 30 s/frame). SPECT data were
reconstructed with iterative methods (ordered subset expecta-
tion maximization, 5 iterations, 8 subsets), following attenua-
tionanddiffusioncorrection,andthenfusedwithCTdatausing
a Syngo data-processing console display unit (Siemens,
Erlangen, Germany). After the indication was confirmed,
90Y-
microsphere therapy was carried out within 15 days after the
first diagnostic angiography. Post-therapeutic bremsstrahlung
scintigraphy (BS) was carried out (windows 70±15%, 135±
15%, nd 167±15% keV) using both planar imaging (256×256,
5 min) and SPECT/CT (32 projections, 128×128, 180° and
30 s/frame).
Planar images and SPECT/CT data were reviewed inde-
pendently by two nuclear medicine specialists experienced
in radioembolization for liver tumours. In the case of dis-
agreement, a consensus was reached.
Patient follow-up
Patients were followed up at 6 weeks and 3 months, and then
in 3-month intervals in order to assess clinical and biological
tolerance,aswellasresponses using contrast-enhanced CT. In
the case of digestive complaints, a gastroduodenal fibroscopy
was performed. Onlypatientswith atleast 6 monthsoffollow-
up were included in the final analysis.
Results
Digestive MAA uptake or extrahepatic digestive-like uptake
was noted in 81 SPECT/CT scans (Table 1), comprising 31
cases of gastric uptake due to free pertechnetate, as shown by
diffuse, low to moderately intense gastric uptake, associated
with thyroid gland uptake. Therefore, digestive or digestive-
like uptake with a potential impact on patient management
wasobservedin50SPECT/CTscans,correspondingto35.9%
of the imaging procedures performed. Data relating to planar
scintigraphy and SPECT/CT as regards the identification of
abdominal extrahepatic uptake other than pertechnetate are
provided in Table 1.
Table 1 Site and number of extrahepatic uptake detected using planar
imaging and SPECT/CT
Planar acquisition SPECT/CT
Free pertechnetate 30 31
Focal gastroduodenal uptake 0 5
Portal vein thrombosis 0 9
Hepatic artery 0 9
Coil 0 3
Gall bladder 2 17
Falciform artery 6 7
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(Fig. 1) uptake other than free pertechnetate, as defined by
focal and isolated uptake with no concomitant thyroid gland
uptake, corresponding to 4.8% of patients. Among these
patients, a new angiography permitted the identification of
an aberrant artery in the digestive tract of three patients, who
underwent successful coil embolization prior to microsphere
therapy. Concerning the remaining two patients, re-reading
the diagnostic angiograms did not reveal any artery likely to
vascularize the stomach or duodenum, and treatment was also
contraindicatedduetoexcessivelungshuntinginonecaseand
poor targeting in another.
In total, 21 SPECT/CT scans revealed digestive-like up-
take in the area of the hepatic hilum, which after a compar-
ison with contrast-enhanced CT was attributed to uptake by
the vascular structures. Uptake was due to main portal vein
thrombosis in nine patients (Fig. 2) and hepatic artery in
nine other patients (Fig. 3), while in three patients, uptake
was linked to an accessory gastric artery, which was treated
using coil embolization (Fig. 4). In 18 patients, radioembo-
lization therapy was performed, with none of the patients
presenting digestive complications, although it was contra-
indicated in one case of excessive pulmonary shunting and
in two others with poor targeting. For the eight patients with
portal vein thrombosis uptake who underwent radioemboli-
zation treatment, microsphere uptake was also found on BS.
Among the nine patients with arterial MAA uptake who
underwent microsphere therapy, eight did not present any
uptake on BS (Fig. 3), whereas in the remaining patient,
arterial microsphere uptake was found on BS. Only one of
the three patients with MAA uptake at the coil site showed
uptake on BS. None of the 18 patients undergoing micro-
sphere treatment experienced digestive complications.
Overall, 17 patients presented gall bladder uptake, which
was considered intense in 7 cases, as defined by an uptake
intensity superior to that of healthy hepatic parenchyma, and
weak in 10 cases. For the seven patients with intense uptake,
the catheter could notbe placed more distally, while stimulation
using the cystic artery catheter was possible in two cases prior
to microsphere treatment. BS revealed microsphere uptake in
only two cases, one of which showed uptake following cystic
arterystimulation.There was nouptake in 15 cases,including4
which did not undergo cystic artery stimulation (Fig. 5). All of
the patients presenting MAA uptake by the gall bladder under-
went microsphere treatment and received a 2-week course of
corticosteroids and antibiotics after the injection.
Six patients presented moderate to intense uptake in the
hepatic falciform artery, which was easily recognizable on pla-
nar imaging by its linear trajectory directed towards the umbili-
cus. For a seventh patient with umbilical hernia, uptake by the
anterior abdominal wall was eventually attributed to the hepatic
falciformartery,butonlyafterperformingSPECT/CT.Forsixof
the seven patients, microsphere treatment was performed with-
out prior hepatic artery embolization, whereas treatment was
carried out in the remaining patient following coil embolization
of the hepatic falciform artery. None of the seven patients
experienced abdominal pain following microsphere treatment.
Lastly, in three cases, SPECT/CTinterpretation was rendered
difficult, due to misregistration artefacts, possibly suggesting
gastric uptake in two cases (Fig. 6) and gall bladder uptake in
one. These three patients were treated as a result of the identifi-
cation of the misregistration artefacts when the MAA SPECT/
CT was performed and not when the retrospective data were
analysed. No gastric or biliary complications were observed.
Digestive complications
Following microsphere therapy, one patient suffered from gas-
tric ulcer disease, which necessitated surgical intervention. This
case has already been described [10], with the patient requiring,
immediately prior to the microsphere injection, additional coil
embolization of the left gastric artery, as gastric MAA uptake
was shown on SPECT/CT. The procedure was complicated by
distal coil migration, requiring the insertion of a second coil
located more proximally to the distant coil. The exact aetiology
of the patient’s ulcer could not be established, with possible
Fig. 1 Uptake at the liver hilum–duodenal uptake. A 69-year-old patient
with hepatocellular carcinoma infiltrating the left liver lobe. SPECT/CT
revealed focal MAA uptake at the liver hilum, corresponding to a duode-
nal localization (a), which was not detected on planar imaging. The
patient underwent a second angiography, which allowed identification
of a small supraduodenal artery branch that was successfully treated by
coilembolization.AfterperformingasecondMAASPECT/CT,duodenal
uptake was no longer apparent (b)
874 Eur J Nucl Med Mol Imaging (2012) 39:872–880causes being proximal and distal occlusion of the left gastric
artery resulting in acute gastric ischaemia or local irradiation
relating to the tumour.
Another patient undergoing treatment with
90Y-loaded resin
microspheres presented diffuse erosive gastritis, which oc-
curred during a hypertensive crisis requiring the assistance of
an anaesthetist. This patient presented a history of treated
arterial hypertension, with a recurrence of unifocal HCC on
cirrhosis(Child-PughscoreA5).Forthispatient,neitherdiffuse
nor focal gastric uptake was seen on MAA SPECT/CT, where-
as BS did reveal diffuse gastric uptake of mild intensity, sug-
gestive of microsphere reflux occurring during the injection.
Two patients complained of gall bladder pain, which was
diagnosed as alithiasic cholecystitis, with sludge features
found on ultrasound examination. Both patients’ symptoms
were resolved following medical treatment. In the first case,
MAA SPECT/CTrevealed intense gall bladder uptake, which
was not observed on BS (Fig. 5). As for the second case,
neitherMAASPECT/CTnorBSrevealedgallbladderuptake.
Discussion
Microsphere deposits in the gastrointestinal tract, resulting
in an increased risk of developing gastrointestinal ulcer
disease, are one of the rare complications associated with
radioembolization therapy. A recent review of the published
literature indicated that the incidence of gastrointestinal
ulcers following radioembolization usually ranged from
2.9 to 4.8% [11], sometimes exceeding 10%, and even
approaching 28% [12–14] in certain series with limited
patient numbers. The two major causes thought to be re-
sponsible for gastroduodenal ulcers are: (1) digestive shunt-
ing via an aberrant gastroduodenal vessel that is subjected to
microsphere injection and (2) microsphere reflux occurring
during the injection.
Diagnostic angiography is routinely carried out in order
to detect aberrant collateral gastrointestinal vessels, while
coil embolization is performed in cases where aberrant
vessels are disclosed. The disparities in the reported fre-
quencies may be accounted for by several factors: individual
case complexities, arterial network alterations due to prior
medical or surgical interventions and the different levels of
experience of the interventional radiologists (learning
curve). In addition, the type of microspheres used must also
be taken into account, especially regarding the risk of mi-
crosphere reflux during administration. From a theoretical
point of view, this risk is probably increased when using
resin microspheres rather than glass microspheres, due to
their lower specific activity (50 vs 2,500 Bq/sphere) and a
Fig. 2 Uptake at the liver hilum–portal vein thrombosis. Hepatocellular
carcinoma patientwith main portal vein thrombosis. SPECT/CTrevealed
focal MAA uptake at the liver hilum (a), corresponding to uptake at the
level of the thrombosis clearly seen on the contrast-enhanced CT (b,
portal phase). The patient was successfully treated with an objective
response with portal vein reperfusion without any complications
a b 
Fig. 3 Uptake at the liver hilum–hepatic artery. A 76-year-old patient
with bifocal hepatocellular carcinoma of the right liver lobe. MAA
SPECT/CT revealed intense and focal hyperfixation at the hepatic
hilum (a, ) just below the duodenum corresponding to a
hepatic artery uptake, as hepatic artery is clearly demonstrated at
contrast-enhanced CT (b )
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injected activity. Given this context, it should be noted that
when considering high-volume teams that had treated over
100 patients the risk of ulcer disease after using resin micro-
spheres did not exceed 5.5% [13, 15, 16] and less than 1%
after using glass microspheres [1, 2].
This ulcer type is often severe, and surgical interventions are
required in over 50% of cases, because of the potential patient
resistance to proton pump inhibitors [11], which highlights the
need for effectively identifying high-risk patients. With the
advent of SPECT/CT hybrid systems, MAA hepatic arterial
perfusion scintigraphy may allow detection of digestive shunts,
in addition to diagnostic angiography. However, little data are
available on the subject [6–8], with only two published studies
on SPECT/CT including over 50 patients [6, 7].
In the first study by Hamami et al., SPECT/CT allowed
detection of 16 cases of uptake suggestive of gastroduodenal
shunting, with planar imaging identifying only 4 cases among
the68scansperformed(23%ofcases)[6].Intwocases,anew
diagnostic angiography failed to reveal any aberrant collateral
vessel, and microsphere treatment was therefore contraindi-
cated. In eight cases, a new angiography allowed the radiol-
ogists to identify the aberrant artery, with coil embolization
performed in six patients, while the remaining two underwent
microsphere injection at a more distal site. However, in three
cases, hepatic hilar uptake was initially considered to indicate
digestive shunting, but a comparison with the injected diag-
nostic CTscan eventually revealed that the uptake was due to
portal vein thrombosis. Recently, the same expert team
reported on the results obtained with
90Y-microsphere therapy
in 108 hepatocellular carcinoma patients, with none of the
patients presenting gastric ulcer after therapy [2].
Similarly, in a report published by Ahmadzadehfar et al.
involving 90 scans, 42% extrahepatic uptake was detected
Fig. 4 MAA uptake at coil
embolization site. A 71-year-
old patient with inoperable
centrohepatic cholangiocarci-
noma. MAA SPECT/CT (a)
revealed focal hyperfixation at
the coil embolization site after
selective injection into the right
hepatic artery following coil
embolization of the gastroduo-
denal artery. The injection of
1.95 GBq glass microspheres
was performed, vascular uptake
not being taken into account.
Post-treatment BS (b) showed
no microsphere uptake at the
coil embolization site. Treat-
ment was well tolerated
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Fig. 5 Gall bladder uptake. A 75-year-old patient with unifocal recur-
rence of hepatocellular carcinoma at the 5/6 liver segments after
chemoembolization. a Planar MAA scintigraphy: heterogeneous liver
uptake. b MAA SPECT/CT: high uptake by gall bladder, tumour and
hepatic artery. c Post-treatment BS: absence of hyperfixation of the gall
bladder despite the absence of cystic artery stimulation. The patient
experienced an episode of subhepatic pain with a vesicular sludge,
referred to as alithiasic cholecystitis, which resolved after medical
treatment; its relationship to the radioembolization procedure remains
unclear because of the absence of gall bladder hyperfixation
Fig. 6 Coregistration error. A 69-year-old patient with variant hepatic
arterial anatomy presenting three hepatic arteries and multifocal hepa-
tocellular carcinoma in segment 1, infiltrating the left liver lobe,
associated with portal vein thrombosis. a MAA SPECT/CT following
selective injection into the left hepatic artery: extrahepatic uptake,
probably corresponding to the gastric wall. Because of segment 1
involvement and due to the lack of portal vein thrombosis targeting,
a second MAA SPECT/CT was performed at the middle hepatic artery
level (b) highlighting a coregistration error at the tip of the left liver
lobe, with CT identification of a hepatic tongue, extending along the
left gastric border. The suspected diagnosis was a small-sized lesion at
the tip of the left liver lobe. It was therefore decided to perform first-
line treatment of the middle hepatic artery. During the procedure,
selective lipiodol arteriography of the left hepatic artery was con-
ducted, with CT lipiodol (c) confirming the presence of a hepatic
tongue, along with a nodular lesion taking up lipiodol. Thereafter,
2 months after the first treatment, the patient underwent treatment of
the left hepatic artery. The treatment was well tolerated, with the
patient being still alive, with good tumour control, 11 months after
the first treatment
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ing [7]. These results took into account four cases of gastric
uptake in relation to free pertechnetate and nine cases of gall
bladder uptake. Gastric or duodenal uptake was found 18
times, corresponding to 20% of cases. For nine patients, re-
reading the diagnostic angiograms allowed radiologists to
detect an aberrant vessel, which was treated by embolization
or distal microsphere injections. For two patients, there was
no aberrant vessel detected while re-reading diagnostic
angiograms, and in both cases, microsphere treatment was
considered contraindicated. For four patients, the duodenum
was only identified a posteriori as the specific site of uptake
following retrospective data analysis. Of these four patients,
two developed ulcer disease, one did not undergo treatment
because of pulmonary shunting, while the remaining patient
underwent coil embolization of the aberrant vessel during
therapy. Other uptake sites were found including coil em-
bolization (n06), intestinal region (n09), spleen (n02),
abdominal wall (n03) and diaphragm (n01).
The recently published study of Dudeck et al. [9] on re-
angiography following positive MAA SPECT/CT found
that among 341 patients gastroduodenal uptake was identi-
fied in 33 patients (9.7%) using SPECT/CT, while at repeat
angiography the source of extrahepatic flow was identified
and corrected in 31 patients.
Our findings are in line with published data [6, 7, 9],
demonstrating that SPECT/CT enabled the identification of
digestive shunts that were previously overlooked by selec-
tive angiography. However, in our series, the incidence rate
of digestive shunts that went unnoticed was lower, repre-
senting only 4.8% of cases.
It should be noted that in several cases uptake by
vascular structures or, more rarely, misregistration arte-
facts may render SPECT/CT interpretation difficult
(Table 2). The hepatic hilar area is particularly difficult
to interpret. Uptake in this area may be of duodenal
origin, with a potential impact on treatment decisions,
although it may also be due to vascular structures,
without therapeutic implications.
In this article, we reported for the first time on MAA
uptake by the hepatic artery, observed in 6.6% of explora-
tions, which had no impact on patient management and was
not associated with any complications. These arterial
uptakes are likely due to the impaction or aggregation of
MAA by arterial microlesions caused by the long and com-
plicated angiography procedures or when arteries are weak-
ened by previous procedures. In fact, among the nine
patients with MAA uptake via the hepatic artery, four had
previously been administered intra-arterial therapy, consist-
ing of chemoembolization in three cases and
131I-lipiodol
treatment in one, while one patient had undergone a prior
hepatectomy and another had experienced a difficult angi-
ography due to arterial stenosis. Uptake at the coil emboli-
zation site may have erroneously led to the diagnosis of
duodenal uptake, which was observed in 2.1% of our explo-
rations, compared to 6.6% of the explorations reported by
Ahmadzadehfar et al.
While uptake by portal vein thrombosis was reported in
three cases in the study of Hamami et al., a 6.4% incidence of
portal vein thrombosis uptake was found in our series,
approaching 31% in patients with established portal vein
thrombosis. This critical point must be stressed, as portal vein
thrombosis is a good indication for radioembolization [1, 2].
The presence of free pertechnetate was another source of
interpretation error when using SPECT/CT. However, due to
the diffuse nature of gastric uptake along with the associated
thyroid uptake, it was easy to recognize. Several authors
recommend using perchlorate to reduce potential errors [17].
Generally, MAA uptake via the hepatic falciform artery
does not result in diagnostic problems except for patients with
umbilical hernia. Although coil embolization is usually rec-
ommended prior to microsphere injection, the risk of compli-
cations appears to be low, since six of our seven patients who
received microsphere injections without prior embolization
Table 2 Site and frequency of digestive extrahepatic uptake (expressed as percentage of number of SPECT/CT by study), other than free
pertechnetate, reported in the literature
Current study Hamami et al. [6] Ahmadzadehfar et al. [7] Dudeck et al. [9] Denecke et al. [8]
Number of SPECT/CT 139 68 90 341 28
Focal gastroduodenal uptake (%) 3.6 23.5 24.4 9.7 31
Portal vein thrombosis uptake (%) 6.5 4.4 NR NR NR
Hepatic artery uptake (%) 6.5 NR NR NR NR
Coil uptake (%) 2.1 NR 6.6 NR NR
Gall bladder uptake (%) 12.2 8.8 10 NR NR
Falciform artery uptake (%) 5.0 NR 3.3 NR NR
Other uptake (%) 0 NR Spleen: 2.2 NR NR
Intestine: 10
Diaphragm: 1.1
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falciform artery was identified using MAA SPECT/CT a
posteriori in 16 patients who did not undergo coil emboliza-
tionduringtreatment;only1 patient complainedofabdominal
pain for 48 h, without presenting skin lesions [18]. However,
identifying a falciform artery and the associated low risk of
abdominal pain is important on the one hand to properly
inform the patient and on the other to avoid performing
multiple and unnecessary endoscopies to detect ulcer disease
in patients with unexplained abdominal pain.
Furthermore, SPECT/CTallowed detection of gall bladder
uptake, which was not identifiedusing planar imaging,as was
the case in 12.2% of the explorations in the present study.
Although no particular problems were associated with the
operational strategy for patients with low-intensity uptake (i.e.
inferior to hepatic parenchymal uptake), high-intensity uptake
remained a therapeutic challenge with no established consensus.
The therapeutic decision must be made on a case-by-case
basis following a precise evaluation of the benefit-risk
balance.
The risk of acute cholecystitis is known, with several
cases being reported in the literature [19]. However, its
frequency appears to be very low given that in a large
retrospective multicentre study on 515 patients no case of
cholecystitis was reported [20]. Nevertheless, this compli-
cation may be treated surgically as was described for two
patients presenting acute cholecystitis [19].
In cases where distal positioning of the catheter was not
possible, Hamami et al. [6] performed a preventive chole-
cystectomy in 2 patients, while Ahmadzadehfar et al. [7]
carried out coil embolization of the cystic artery in 1 patient
and Dudeck et al. [9] in 13, with no complications being
observed. In our series, prior to microsphere injection, we
performed a catheter stimulation of the cystic artery in two
of seven patients with high MAA uptake, for whom this
procedure was possible. It is interesting to note that for four
patients with intense MAA uptake by the gall bladder no
uptake was observed on BS, despite the catheter being in the
identical position and the absence of any cystic artery stim-
ulation, which was likely to be due to the instability or
vasomotor variability of the cystic artery (Fig. 5). The
decision to treat the seven patients with intense gall bladder
uptake was taken on a case-by-case basis following a
benefit-risk evaluation. It was taken into account that five
of these patients required salvage treatment in the setting of
very advanced tumour disease, with four presenting portal
vein thrombosis. For the two remaining patients, vasomotor
variability of the cystic artery was identified in the absence
of microspheres on BS. These patients received prophylactic
therapy with anti-inflammatory drugs and antibiotics for
14 days following treatment.
Lastly, SPECT/CT interpretation may lead to diagnostic
problems if coregistration errors occur due to diaphragm
movements. Although poorly documented in the scientific
literature, the frequency of these artefact types may be signif-
icant when exploring moving anatomical structures. In fact,
for the liver, Vogel et al. reported the risk of misregistration
errors to be 30–40% of cases using positron emission tomog-
raphy (PET)/CT according to respiratory status (expiration
breath-hold or free breathing), with the mean error of posi-
tioning being >1 cm (range 4–16 mm for free breathing) [21].
Therefore, a coregistration error should be considered system-
atically before drawing any final conclusion on digestive tract
uptake, performing another angiography or contraindicating
microsphere therapy definitively.
Conclusion
This study confirms previously published data suggesting
the superiority of SPECT/CT over planar imaging for the
identification of digestive, extrahepatic MAA uptake sites,
which were found in more than one third of our cases,
including gall bladder uptake. MAA SPECT/CT should
now be recommended in the preoperative assessment prior
to radioembolization in order to better identify the risk of
digestive shunts. In cases of gastroduodenal uptake on
MAA SPECT/CT, a repeat angiographic assessment is man-
datory as the source of gastroduodenal flow can frequently
be identified and corrected. However, our series revealed a
high frequency of vascular uptake (20.1%) at the level of
portal vein thrombosis, hepatic artery or coil embolization
sites, without any consequences for the therapeutic manage-
ment of patients. These uptake sites must be recognized by
experts, as should coregistration errors, in order to avoid the
risk of excluding patients who do not present any contra-
indications to radioembolization from this effective thera-
peutic strategy.
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